QuidelOrtho and Lifotronic agree on global immunoassay portfolio expansion

Core Insights - QuidelOrtho has entered a strategic supply agreement with Lifotronic Technology to expand its global immunoassay portfolio, focusing on high-throughput and low-to-mid volume immunoassay analyzers [1] - The partnership aims to provide cost-efficient and scalable diagnostic solutions in selected international markets outside the US, enhancing QuidelOrtho's competitive edge [1][4] Product Expansion - The agreement will introduce over 25 new assays not currently available on QuidelOrtho's VITROS system, increasing the total number of assays on the new platforms to more than 70 [2] - This expansion is designed to meet broader tender requirements and cater to various laboratory environments, from low-volume solutions to larger settings [2][3] Market Impact - Laboratories will benefit from the expanded offering, which addresses menu gaps and enhances competitiveness in international tenders by providing more flexible system options [3] - QuidelOrtho's senior vice-president emphasized that the collaboration will accelerate the introduction of scalable testing solutions, aligning with the company's long-term innovation strategy in core growth markets [4]